Senzo Health, a London, UK-based life sciences company developing diagnostic technologies, raised additional $1.8M in funding.
The backers were not disclosed.
The company intends to use the funds to continue to expand operations and its development efforts.
Led by Jeremy Stackawitz, Senzo is an in vitro diagnostics company developing a laboratory-accurate lateral flow test. Today, for many infections, diseases, and patients, laboratory diagnostics are too slow or too expensive. To solve this problem, the company is developing a 10-minute lateral flow test with the same accuracy as a laboratory PCR test.
Senzo is progressing tests for a wide range of high-need applications, including RSV, Influenza A/B, COVID-19, STIs, Tuberculosis, Hepatitis B and C, AMR, HIV, C. difficile/Staph/MRSA, Lyme Disease, Veterinary, and Environmental/Industrial.
FinSMEs
11/10/2023